Osteosarcoma Clinical Trials

75 recruitingLast updated: June 17, 2026

There are 75 actively recruiting osteosarcoma clinical trials across 18 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3. Top locations include Atlanta, Georgia, United States, Boston, Massachusetts, United States, Memphis, Tennessee, United States. Updated daily from ClinicalTrials.gov.


Osteosarcoma Trials at a Glance

75 actively recruiting trials for osteosarcoma are listed on ClinicalTrialsFinder across 6 cities in 18 countries. The largest study group is Phase 1 with 33 trials, with the heaviest enrollment activity in Atlanta, Boston, and Memphis. Lead sponsors running osteosarcoma studies include St. Jude Children's Research Hospital, Peking University People's Hospital, and Children's Oncology Group.

Browse osteosarcoma trials by phase

Treatments under study

About Osteosarcoma Clinical Trials

Looking for clinical trials for Osteosarcoma? There are currently 60 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Osteosarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Osteosarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 75 trials

Recruiting
Phase 1

Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma

OsteosarcomaSoft Tissue Sarcoma (STS)
Sun Yat-sen University16 enrolled1 locationNCT07648069
Recruiting
Phase 2Phase 3

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Metastatic OsteosarcomaHigh Grade OsteosarcomaLocalized Osteosarcoma+1 more
National Cancer Institute (NCI)1,122 enrolled197 locationsNCT05691478
Recruiting
Phase 1Phase 2

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

OsteosarcomaEwing SarcomaNeuroblastoma+4 more
Milton S. Hershey Medical Center289 enrolled10 locationsNCT06465199
Recruiting
Phase 2

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

OsteosarcomaEwing SarcomaEwing Sarcoma Metastatic
Milton S. Hershey Medical Center406 enrolled2 locationsNCT07321912
Recruiting
Phase 1

Losartan + Sunitinib in Treatment of Osteosarcoma

Osteosarcoma
University of Colorado, Denver41 enrolled4 locationsNCT03900793
Recruiting
Phase 1Phase 2

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

AngiosarcomaLiposarcomaAdipocytic Neoplasm+6 more
St. Jude Children's Research Hospital139 enrolled7 locationsNCT06239272
Recruiting
Not Applicable

Musculoskeletal Cancers Remote Monitoring and Care

OsteosarcomaMetastatic Bone Disease
Case Comprehensive Cancer Center60 enrolled1 locationNCT07129226
Recruiting
Phase 1

Safety and Feasibility of Intraoperative Visualization With Cytalux in Children

Metastatic SarcomaOsteosarcomaPulmonary Metastasis+2 more
Ann & Robert H Lurie Children's Hospital of Chicago10 enrolled1 locationNCT06235125
Recruiting
Early Phase 1

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

transitional cell carcinomaSoft Tissue SarcomaMelanoma+12 more
University of California, Irvine25 enrolled1 locationNCT07628634
Recruiting
Phase 1Phase 2

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

ParagangliomaPheochromocytomaSolid Tumor Cancer+19 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Phase 1

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

OsteosarcomaPulmonary Recurrence of Osteosarcoma
Emory University12 enrolled1 locationNCT06492954
Recruiting
Phase 1

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

Refractory OsteosarcomaOsteosarcoma in ChildrenOsteosarcoma Recurrent+1 more
Emory University24 enrolled1 locationNCT07144254
Recruiting
Phase 2

Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma

OsteosarcomaSoft Tissue Sarcoma (STS)
Sun Yat-sen University57 enrolled1 locationNCT07602049
Recruiting
Phase 2

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

Pediatric Osteosarcoma
St. Jude Children's Research Hospital41 enrolled1 locationNCT07428993
Recruiting
Phase 1Phase 2

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Solid Tumor+19 more
St. Jude Children's Research Hospital90 enrolled10 locationsNCT04901702
Recruiting
Phase 1

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Soft Tissue SarcomaMelanomaCarcinoma+13 more
St. Jude Children's Research Hospital48 enrolled1 locationNCT04897321
Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

OsteosarcomaRecurrent LymphomaLymphoblastic Lymphoma+4 more
Children's Oncology Group420 enrolled79 locationsNCT01790152
Recruiting
Phase 1Phase 2

DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma

Osteosarcoma RecurrentEwing's Tumor Recurrent
Montefiore Medical Center15 enrolled1 locationNCT06892678
Recruiting
Phase 1

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Triple-Negative Breast CancerColorectal, CancerSarcoma+5 more
Valo Therapeutics Oy15 enrolled7 locationsNCT05492682
Recruiting

An Organoid-based Functional Precision Medicine Trial in Osteosarcoma

Osteosarcoma
Jonsson Comprehensive Cancer Center40 enrolled1 locationNCT06064682